Control of mineral homeostasis is a particularly challenging task in children and adolescents on dialysis. Treatment efforts must not only ensure patient survival and the absence of debilitating complications of bone disease, but in view of a potentially long lifespan, must also consider how to best promote long-term cardiovascular health and successful psychosocial transition into adult life. In that context, avoidance of cardiovascular calcifications and accomplishment of adequate statural growth and a normal final height are major objectives of uremic bone disease management in children. Unfortunately, current pediatric management guidelines operate on a small evidence base, and major controversy surrounds key issues such as optimal target ranges for serum parathyroid hormone, calcium, and phosphorus in the individual childhood phases, and individual risk–benefit ratios for the use of phosphate binders, vitamin D analogs, and calcimimetics in children. The present review summarizes the current state of knowledge and outlines future research requirements in bone disease associated with pediatric end-stage renal disease.
KlausG., WeberL., RodríguezJ., FernándezP., KleinT., Grulich–HennJ.Interaction of IGF-I and 1 alpha, 2 5 (OH)2D3 on receptor expression and growth stimulation in rat growth plate chondrocytes.Kidney Int1998; 53: 1152–61.
2.
GreenJ., GoldbergR., MaorG.PTH ameliorates acidosis-induced adverse effects in skeletal growth centers: the PTH-IGF-I axis.Kidney Int2003; 63: 487–500.
3.
MehlsO., RitzE., GilliG., WangdakT., KrempienB.Effect of vitamin D on growth in experimental uremia.Am J Clin Nutr1978; 31: 1927–31.
ChanJ.C., McEneryP.T., ChinchilliV.M., AbitbolC.L., BoineauF.G., FriedmanA.L.A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators.J Pediatr1994; 124: 520–8.
6.
KuizonB.D., GoodmanW.G., JüppnerH., BoechatI., NelsonP., GalesB.Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD.Kidney Int1998; 53: 205–11.
7.
SanchezC.P., KuizonB.D., AbdellaP.A., JüppnerH., SaluskyI.B., GoodmanW.G.Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure.Endocrinology2000; 141: 1536–44.
8.
SchmittC.P., HessingS., OhJ., WeberL., OchlichP., MehlsO.Intermittent administration of parathyroid hormone (1–37) improves growth and bone mineral density in uremic rats.Kidney Int2000; 57: 1484–92.
9.
VortkampA., LeeK., LanskeB., SegreG.V., KronenbergH.M., TabinC.J.Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein.Science1996; 273: 613–22.
10.
SchmittC P., ArdissinoG., TestaS., Claris-AppianiA., MehlsO.Growth in children with chronic renal failure on intermittent versus daily calcitriol.Pediatr Nephrol2003; 18: 440–4.
11.
WallerS.C., RidoutD., CantorT., ReesL.Parathyroid hormone and growth in children with chronic renal failure.Kidney Int2005; 67: 2338–45.
12.
CansickJ., WallerS., RidoutD., ReesL.Growth and PTH in prepubertal children on long-term dialysis.Pediatr Nephrol2007; 22: 1349–54.
13.
LitwinM., WühlE., JourdanC., TrelewiczJ., NiemirskaA., FahrK.Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation.J Am Soc Nephrol2005; 16: 1494–500.
14.
MillinerD.S., ZinsmeisterA.R., LiebermanE., LandingB.Soft tissue calcification in pediatric patients with end-stage renal disease.Kidney Int1990; 38: 931–6.
15.
CivilibalM., CaliskanS., AdaletliI., OflazH., SeverL., CandanC.Coronary artery calcifications in children with end-stage renal disease.Pediatr Nephrol2006; 21: 1426–33.
16.
OhJ., WunschR., TurzerM., BahnerM., RaggiP., QuerfeldU.Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure.Circulation2002; 106: 100–5.
17.
GoodmanW.G., GoldinJ., KuizonB.D., YoonC., GalesB., SiderD.Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.N Engl J Med2000; 342: 1478–83.
18.
ArakiY., HatayaH., TanakaY., FukuzawaR., IkedaM., KawamuraK.Long-term peritoneal dialysis is a risk factor of sclerosing encapsulating peritonitis for children.Perit Dial Int2000; 20: 445–51.
NKF K/DOQI Clinical Practice guidelines for bone metabolism and disease in children with chronic kidney disease.Am J Kidney Dis2005; 46(Suppl 1).
21.
European Society for Paediatric Nephrology (ESPN).ESPN Handbook.Lyon, France: Medcom; 2002: 461.
22.
SaluskyI.B., KuizonB.D., BelinT.R., RamirezJ.A., GalesB., SegreG.V.Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intra-peritoneal administration.Kidney Int1998; 54: 907–14.
23.
SaluskyI.B., RamirezJ.A., OppenheimW., GalesB., SegreG.V., GoodmanW.G.Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.Kidney Int1994; 45: 253–8.
24.
Gal–MoscoviciA., PopovtzerM.M.New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.Clin Nephrol2005; 63: 284–9.
25.
JohnM.R., GoodmanW.G., GaoP., CantorT.L., SaluskyI.B., JüppnerH.A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure.J Clin Endocrinol Metab1999; 84: 4287–90.
26.
TheintzG., BuchsB., RizzoliR., SlosmanD., ClavienH., SizonenkoP.C.Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects.J Clin Endocrinol Metab1992; 75: 1060–5.
27.
ParsonsT.J., PrenticeA., SmithE.A., ColeT.J., CompstonJ.E.Bone mineral mass consolidation in young British adults.J Bone Miner Res1996; 11: 264–74.
28.
RauchenzaunerM., SchmidA., Heinz–ErianP., KapelariK., FalkensammerG., GriesmacherA.Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years.J Clin Endocrinol Metab2007; 92: 443–9.
29.
KlausG., WatsonA., EdefontiA., FischbachM., RönnholmK., SchaeferF. for the European Pediatric Dialysis Working Group (EPDWG). Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.Pediatr Nephrol2006; 21: 151–9.
30.
SaluskyI.B., GoodmanW.G., SahneyS., GalesB., PerillouxA., WangH.J.Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.J Am Soc Nephrol2005; 16: 2501–8.
31.
PieperA.K., HaffnerD., HoppeB., DittrichK., OffnerG., BonzelK.E.A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD.Am J Kidney Dis2006; 47: 625–35.
32.
FerraraE., LemireJ., ReznikV.M., GrimmP.C.Dietary phosphorus reduction by pretreatment of human breast milk with sevelamer.Pediatr Nephrol2004; 19: 775–9.
33.
BrennanA., AkehurstR., DavisS., SakaiH., AbbottV.The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.Value Health2007; 10: 32–41.
34.
LacourB., LucasA., AuchèreD., RuellanN., de Serre PateyN.M., DrüekeT.B.Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.Kidney Int2005; 67: 1062–9.
35.
FischbachM., TerzicJ., MenouerS., DheuC., SoskinS., HelmstetterA.Intensified and daily hemodialysis in children might improve statural growth.Pediatr Nephrol2006; 21: 1746–52.
36.
AndressD.L., NorrisK.C., CoburnJ.W., SlatopolskyE.A., SherrardD.J.Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.N Engl J Med1989; 321: 274–9.
37.
CaravacaF., CuberoJ.J., JimenezF., LópezJ.M., AparicioA., CidM.C.Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.Nephrol Dial Transplant1995; 10: 665–70.
38.
IndridasonO.S., QuarlesL.D.Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.Kidney Int2000; 57: 282–92.
39.
ArdissinoG., SchmittC.P., BianchiM.L., DaccòV., Claris–AppianiA., MehlsO.No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.Kidney Int2000; 58: 981–8.
40.
ArdissinoG., SchmittC.P., TestaS., Claris-AppianiA., MehlsO.Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure.Pediatr Nephrol2000; 14: 664–8.
41.
TengM., WolfM., LowrieE., OfsthunN., LazarusJ.M., ThadhaniR.Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.N Engl J Med2003; 349: 446–56.
42.
TengM., WolfM., OfsthunM.N., LazarusJ.M., HernánM.A., CamargoC.A.Jr.Activated injectable vitamin D and hemodialysis survival: a historical cohort study.J Am Soc Nephrol2005; 16: 1115–25.
43.
GreenbaumL.A., BenadorN., GoldsteinS.L., ParedesA., MelnickJ.Z., MattinglyS.Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.Am J Kidney Dis2007; 49: 814–23.
44.
NakagawaK., GeldyyevA., OhJ., GrossM.L., SantosF., SchaeferF.Calcimimetics do not alter epiphyseal growth in healthy and uremic rats (Abstract).J Am Soc Nephrol2006; 17: 132A.
45.
JuergensenP., ErasJ., McClureB., KligerA.S., FinkelsteinF.O.The impact of various cycling regimens on phosphorus removal in chronic peritoneal dialysis patients.Int J Artif Organs2005; 28: 1219–23.
46.
HaasS., SchmittC.P., ArbeiterK., BonzelK.E., FischbachM., JohnU.Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis.J Am Soc Nephrol2003; 14: 2632–8.
47.
SchmittC.P., von HeylD., RiegerS., ArbeiterK., BonzelK.E., FischbachM. for the Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS). Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content.Nephrol Dial Transplant2007; 22: 2038–44.
48.
ZeierM., SchwengerV., DeppischR., HaugU., WeigelK., BahnerU.Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?Kidney Int2003; 63: 298–305.
49.
HeinG.E.Glycation endproducts in osteoporosis—is there a pathophysiologic importance?Clin Chim Acta2006; 371: 32–6.
